The present invention provides a pharmaceutical composition for the oral administration of an h2 -antagonist. The composition includes an h2 -antagonist and a silicate taste-masking agent capable of forming an adsorbate complex with the h2 -antagonist wherein the complex exhibits a non-bitter taste. The complex inhibits the release of the h2 -antagonist in the oral cavity.
|
13. A pharmaceutical composition for the oral administration of a therapeutically effective amount of an h2 -antagonist, wherein said composition exhibits a non-bitter taste, said composition comprising a non-bitter tasting adsorbate complex of ranitidine hydrochloride and magnesium aluminum silicate, and a dissociation agent consisting of calcium carbonate.
14. A pharmaceutical composition for the oral administration of a therapeutically effective amount of an h2 -antagonist, wherein said composition exhibits a non-bitter taste, said composition comprising a non-bitter tasting adsorbate complex of ranitidine hydrochloride and magnesium aluminum silicate, a dissociation agent consisting of calcium carbonate, and an a flavoring agent selected from the group consisting of citric acid and xylitol.
15. A method for enhancing the release of an h2 -antagonist from an oral pharmaceutical formulation comprising an adsorbate complex, said adsorbate complex consisting essentially of a therapeutically effective amount of an h2 -antagonist and a silicate taste-masking agent, said method comprising incorporating into said pharmaceutical formulation a dissociation agent that enhances the release of said h2 -antagonist from said adsorbate complex, wherein said dissociation agent comprises calcium carbonate.
1. A pharmaceutical composition for the oral administration of a therapeutically effective amount of an h2 -antagonist, wherein said composition exhibits a non-bitter taste, said composition consisting essentially of an h2 -antagonist, a silicate taste-masking agent capable of forming an adsorbate complex with said h2 -antagonist, wherein said complex inhibits the release of the h2 -antagonist in the oral cavity, and between about 2.5 and about 10 percent based upon the weight of the composition of a dissociation agent capable of enhancing the release of said h2 -antagonist from said adsorbate complex, wherein said dissociation agent comprises calcium carbonate.
2. The pharmaceutical composition according to
3. The pharmaceutical composition according to
4. The pharmaceutical composition according to
6. The pharmaceutical composition according to
7. The pharmaceutical composition according to
8. The pharmaceutical composition according to
12. The pharmaceutical composition according to
|
|||||||||||||||||||||||||||||||||||||||||
This application is a continuation-in-part of U.S. application Ser. No. 08/288,711, filed Aug. 12, 1994, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 08/107,126, filed Aug. 17, 1993, now abandoned.
The present invention relates to pharmaceutical compositions containing as the active ingredient, an H2 -antagonist, and more particularly to pharmaceutical compositions useful for the oral administration of a therapeutically effective amount of an H2 -antagonist.
The H2 -antagonist agents (hereinafter "H2 -antagonists") are routinely administered orally to patients suffering from gastrointestinal conditions such as ulcers, dyspepsia, various reflux indications and the like. Typically, the H2 -antagonist is delivered to the patient in tablet or powder-filled capsule form. Other liquid oral compositions such as syrups have also been proposed (see, for example, U.S. Pat. No. 4,128,658 to Price et al.)
The H2 -antagonists are known to have an unpalatably bitter taste when ingested in any form other than solid capsule or tablet form. However, certain segments of the patient population prefer more easily ingested product forms, including chewable tablets, lozenges or troches. Several attempts, with somewhat limited success, have been made to produce a pharmaceutical composition for oral administration which contains an H2 -antagonist. For example, U.S. Pat. No. 5,219,563 to Douglas et al. proposes drug adsorbates for masking the bitter taste of ranitidine which include synthetic cation exchange resins. PCT Publication No. WO 94/0856 to Glaxo proposes chewable tablets of ranitidine, which include an intense sweetener such as aspartame. PCT Publication No. WO94/08576 to Glaxo proposes taste-masked compositions of ranitidine comprising a dispersion of lipid coated ranitidine particles in a non-aqueous vehicle. U.S. Pat. No. 5,260,072 to Roche et al. proposes chewable tablets of H2 -antagonists which contain retrogranules of the drug coated with cellulose acetate, cellulose acetate butyrate or a combination thereof to mask the taste of the H2 -antagonist. U.S. Pat. No. 5,084,278 to Mehta proposes taste-masked ranitidine chewable tablets containing a medicinal core coated with a polymeric coating. U.S. Pat. No. 5,275,823 to France et al. proposes chewable tablets of cimetidine contaiing hygroscopic water-insoluble substances, such as polysaccharides, as extra-granular excipients.
Attempts at taste-masking other pharmaceutical agents have also been proposed. For example, U.S. Pat. No. 4,711,774 to Denick, Jr. et al. proposes a magnesium aluminum silicate as an adsorbate for analgesics, antiasthmatics, antitussives, antihistamines, and other drugs. U.S. Pat. No. 3,140,978 to Zentner also proposes magnesium aluminum silicate pharmaceutical compositions. Neither of these references discloses or suggests masking the bitter taste of an H2 -antagonist with aluminum magnesium silicate.
Accordingly, there remains a need in the art for methods of taste-masking H2 -antagonists for the preparation of oral dosage units containing the same. Moreover, there remains a need in the art for pharmaceutical compositions for the oral administration of H2 -antagonists.
The present invention provides a pharmaceutical composition for the oral administration of an H2 -antagonist. The composition includes an H2 antagonist and a taste-masking agent capable of forming an adsorbate complex with the H2 -antagonist wherein the complex exhibits a non-bitter taste. The complex inhibits the release of the H2 -antagonist in the oral cavity. The taste-masking agent generally comprises a silicate. As used herein, the term "silicate" refers to any of various forms of natural and synthetic clays having one or more Si-O groups in its molecular structure. In one preferred embodiment, the taste-masking agent is magnesium aluminum silicate.
The composition is preferably provided in the form of an oral dosage unit, such as a chewable or frangible tablet, a lozenge, or granules for oral administration to a patient in need thereof. The adsorbate complex masks the bitter taste of the H2 -antagonist such that the pharmaceutical composition does not exhibit any bitter taste to the patient.
H2 -antagonists are derivatives of histamine that bind to and exhibit inhibiting or blocking activity against H2 receptors. The H2 -antagonists, or "H2 -blocking agents," are a discrete and limited group of medications readily recognized in the art, and are generally polar, hydrophilic molecules. See, Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th ed. pp 624-625 (1985). Most pharmaceutical formulations which employ H2 -antagonists, however, have an unpalatably bitter taste. Examples of H2 -antagonists include but are not limited to ranitidine, cimetidine, nizatidine, famotidine, sufotidine, roxatidine, bisfentidine, tiotidine, lamtidine, niperotidine, mifentidine, zaltidine, and loxtidine. H2 -antagonists that are imidazole derivatives (e.g., cimetidine) and furan derivatives (e.g., ranitidine) are preferred. Ranitidine is currently most preferred.
The pharmaceutically active agents useful in the present invention are preferably provided in the form of a pharmaceutically acceptable salt or a free base. Suitable salts are readily available and well known in the art. The preferred pharmaceutically acceptable salts are water soluble. The H2 -antagonists may be provided in a variety of water-soluble salt forms. Suitable water soluble salt forms include hydrochloride salts, hydrobromide salts, sulfate salts, nitrate salts, citrate salts and tartrate salts. The hydrochloride salts are currently preferred.
The amount of H2 -antagonist, either in salt form or free base, which is included in the composition of the present invention will be dependent upon the pharmaceutical activity of the particular compound. Generally, the amount of H2 -antagonist is sufficient to deliver a therapeutically effective dose to a patient in need thereof. For example, the amount of H2 -antagonist typically included in the composition is between about 5 to about 50 percent by weight. Preferably, the amount of H2 -antagonist included in the composition is sufficient to provide an oral dosage form containing between about 5 to about 20 percent by weight of H2 -antagonist.
The taste-masking agents employed in the compositions of the present invention include any silicate capable of forming a taste-masked adsorbate complex with the H2 -antagonist to eliminate or reduce the bitter taste. The complex inhibits the release of the H2 -antagonist in the oral cavity. Examples of silicates capable of forming adsorbate complexes with H2 -antagonists include but are not limited to, montmorillonite, attapulgite, magnesium aluminum silicate and other clays. The preferred silicate taste-masking agent is magnesium aluminum silicate. An exemplary magnesium aluminum silicate is sold under the tradename VEEGUM™, by R. T. Vanderbilt Company, Inc. The adsorbate complex formed between the taste-masking agent and the H2 -antagonist masks the typically strong bitter taste of the H2 -antagonist while the composition is in the oral cavity. The complex is dissociated in the gastrointestinal tract to advantageously release the H2 -antagonist therein.
The amount of silicate taste-masking agent incorporated into the compositions is generally sufficient to form an adsorbate complex with the H2 -antagonists, to provide a composition having a non-bitter taste. Preferably, the silicate taste-masking agent is provided in excess, to ensure that no free or uncomplexed H2 -antagonist remains in the composition. Typically, the taste-masking agent is provided in an amount ratio to H2 -antagonist of between about 1 to about 10:1 taste masking agent to H2 -antagonist. Preferably, the ratio of taste-masking agent to H2 -antagonist is about 5:1.
The adsorbate complex of the H2 -antagonist and the taste-masking agent may be released from the pharmaceutical composition in the oral cavity, however, the complex inhibits the release of the H2 -antagonist in the oral cavity, thereby masking the typical bitter taste of the H2 -antagonist. Advantageously, the complex is readily dissociated, and the H2 -antagonist released, in the gastrointestinal tract. To further facilitate the release of the H2 -antagonist in the gastrointestinal tract, the composition of the present invention may also include a dissociation agent, which is capable of assisting in the dissociation of the adsorbate complex in the gastrointestinal tract.
Suitable dissociation agents will be known to those skilled in the art, but preferably include a weak base. Specific examples of suitable dissociation agents include but are not limited to, sodium bicarbonate, calcium carbonate, potassium carbonate, and the like. Calcium carbonate is the preferred dissociation agent. The amount of dissociation agent included in the composition is between about 0 and about 35 percent by weight of the composition. Preferably, the dissociation agent is included in an amount of between about 5 and about 20 percent by weight of the composition.
As will be known in the art, the pharmaceutical composition of the present invention may also include other excipients commonly employed for the formation of a variety of dosage unit forms. For example, the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier such as microcrystalline cellulose or lactose, flavoring agents and/or sweeteners, artificial colorings, tableting excipients such as bulking agents and/or granulating agents, buffering agents, lubricants, preservatives, and the like. Suitable flavoring agents and sweeteners, include natural and artificial flavorings such as citric acid, maleic acid, tartaric acid, xylitol, mannitol, saccharin, sugar, sorbitol, maltitol, and the like. Preferred flavoring agents including citric acid, maleic acid, tartaric acid, xylitol, and mannitol. Suitable bulking agents include mannitol, xylitol, and microcrystalline cellulose. Xylitol and mannitol are particularly preferred as sweetening and bulking agents. Suitable lubricants include magnesium stearate.
The composition is preferably provided in the form of an oral dosage unit, such as a chewable or frangible tablet, a lozenge, or granules for oral administration to a patient in need thereof. According to one preferred embodiment, the pharmaceutical composition of the present invention is provided in the form of a chewable tablet. A suitable chewable tablet formulation will include between about 5 and about 20 percent by weight of the pharmaceutical composition of the present invention, and conventional chewable tablet excipients such as those described in U.S. Pat. No. 5,225,197 to Bolt et al., the disclosure of which is incorporated herein by reference in its entirety.
The pharmaceutical compositions of the present invention may be prepared using conventional oral dosage form equipment. According to one preferred method, the pharmaceutical composition may be prepared by dry mixing a pharmaceutically acceptable salt of the H2 -antagonist and the taste-masking agent to provide a substantially uniform admixture. Thereafter sufficient water is added to form a substantially uniform wet mass. The H2 -antagonist is solubilized by the added water, and the adsorbate complex forms readily, in situ. Thereafter, the wet mass is dried according to conventional techniques, and if necessary, the resulting powder is milled to achieve the desired particle size. Optionally, a predetermined quantity of a dissociation agent may be incorporated into the composition by dry mixing the dissociation agent and the dried pharmaceutical composition after milling. Other pharmaceutical excipients, as described above, may be added after milling to form the oral dosage unit. The oral dosage unit may then be compressed into tablet form to provide a chewable tablet.
According to a second preferred embodiment, the pharmaceutical composition of the present invention may be prepared by dry mixing the free base of the H2 -antagonist and the taste-masking agent to provide a substantially uniform admixture. Thereafter a sufficient quantity of dilute acid, such as hydrochloric acid is added to form a substantially uniform wet mass. The H2 -antagonist is solubilized by the added acid, and the adsorbate complex forms readily, in situ. Thereafter, the oral dosage form may be prepared according to the steps outlined above.
One skilled in the art will appreciate that other excipients may be employed, and other oral dosage forms may be prepared using techniques which are well known in the art. Accordingly, one skilled in the art will appreciate that the present invention contemplates the preparation of such dosage forms.
The daily dose of any particular H2 -antagonist may be provided in the form of one or more oral dosage units containing the pharmaceutical composition according to the present invention. The daily dose of the H2 -antagonist is non-toxic and therapeutically effective. Typically, the daily dose of H2 -antagonist is from 40 to 1600 mg, depending upon the particular H2 -antagonist to be administered. For example, the suggested daily dose of ranitidine and nizatidine is 300 mg, cimetidine is 800 mg, and famotidine is 40 mg. See, Histamine and Histamine antagonists, Handbook Exp. Pharmacol. 97: 573 (1991), the disclosure of which is incorporated herein by reference in its entirety. The oral dosage unit may include a dose of from 10 to 800 mg of H2 -antagonist, depending on the known pharmaceutical activity and market of the H2 -antagonist drug. Typically, the dosage units are administered orally from 1 to 5 times daily.
The following examples are provided to illustrate the present invention, and should not be construed as limiting thereof.
This example shows the preparation of chewable tablets. The ingredients are shown in Table 1.
| TABLE 1 |
| ______________________________________ |
| % By Weight |
| Ingredients A B C D |
| ______________________________________ |
| Nizatidine 5 -- -- -- |
| Cimetidine -- 5 -- -- |
| Ranitidine -- -- 5 -- |
| Famotidine -- -- -- 2 |
| Magnesium Aluminum Silicate NF |
| 25 25 25 10 |
| Sodium Saccharin NF .25 .25 .25 .125 |
| Mannitol NF Q.S. Q.S. Q.S. Q.S. |
| Xylitol NF Q.S. Q.S. Q.S. Q.S. |
| Collodial Silicon Dioxide NF |
| 1 1 1 1 |
| Magnesium Stearate NF |
| 1.5 1.5 1.5 1.5 |
| Flavors Q.S. Q.S. Q.S. Q.S. |
| Purified water* |
| 100 100 100 100 |
| ______________________________________ |
| *Remove during processing |
Method of Manufacturing
1. Mix drug with magnesium aluminum silicate and sodium saccharin in a planetary mixer for five minutes.
2. Add water until a uniform granulation occurs.
3. Dry the granules.
4. Size the granules into fine powder.
5. Add mannitol, xylitol and collodial silicon dioxide and mix for ten minutes.
6. Add magnesium sterate and mix for five minutes.
7. Compress into chewable tablets.
This example shows the preparation of chewable tablets. The ingredients are shown in Table 2.
| TABLE 2 |
| ______________________________________ |
| % By Weight |
| Ingredients A B C D |
| ______________________________________ |
| Nizatidine 5 -- -- -- |
| Cimetidine -- 5 -- -- |
| Ranitidine HCl USP -- -- 5.6 -- |
| Famotidine -- -- -- 2 |
| Magnesium Aluminum Silicate NF |
| 25 25 25 10 |
| Calcium Carbonate USP |
| 5 5 5 5 |
| Sodium Saccharin NF .25 .25 .25 .125 |
| Mannitol NF Q.S. Q.S. Q.S. Q.S. |
| Xylitol NF Q.S. Q.S. Q.S. Q.S. |
| Collodial Silicon Dioxide NF |
| 1 1 1 1 |
| Magnesium Stearate NF |
| 1.5 1.5 1.5 1.5 |
| Flavors Q.S. Q.S. Q.S. Q.S. |
| Purified water* |
| 100 100 100 100 |
| ______________________________________ |
| *Remove during processing |
Method of Manufacturing
1. Mix drug with magnesium aluminum silicate and sodium saccharin in a planetary mixer for five minutes.
2. Add water until a uniform granulation occurs.
3. Dry the granules.
4. Size the granules into fine powder.
5. Add mannitol, xylitol, calcium carbonate, collodial silicon dioxide and mix for ten minutes.
6. Add magnesium sterate and mix for five minutes.
7. Compress into chewable tablets.
If the operator wishes an acid agent such as a fruit acid, for example, citric, malic or tartaric acid in the formulation, this is added to the manufacturing process at Step 1 before the granulation process, usually at about 1.5%.
The following comparative examples were selected to illustrate the enhanced release of active ingredient from the granules/tables of this invention using the preparative and testing procedures described above.
PAC Comparative ExampleThe percentage of cimetidine dissolved in water using the U.S.P. method II at 50 RPM to 60 minutes from granules with added citric acid (3% ), calcium carbonate (75 mg) and without calcium carbonate.
| TABLE 3 |
| ______________________________________ |
| Time (min.) Without CaCO3 |
| With CaCO3 |
| ______________________________________ |
| 15 39.9 67.5 |
| 30 44.6 74.4 |
| 45 46.9 78.8 |
| 60 48.3 82.8 |
| 75 51.6 104.3 |
| ______________________________________ |
Ranitidine Hydrochloride (75 mg base) with Calcium Carbonate (75 mg)
| TABLE 4 |
| ______________________________________ |
| Time (min.) Without CaCO3 |
| With CaCO3 |
| ______________________________________ |
| 15 30.3% 44.0% |
| 30 36.6% 51.4% |
| 45 36.9% 53.7% |
| 60 37.6% 56.8% |
| 40.4% 63.6% |
| ______________________________________ |
Nizatidine with and without calcium carbonate compared at 0 time and 1 month stability (40°; 75% RH), citric acid (1.5%) added to all samples.
| TABLE 5 |
| ______________________________________ |
| Time (min.) |
| Without CaCO3 |
| Stability |
| With CaCO3 |
| Stability |
| ______________________________________ |
| 15 30.3 30.0 77.6 45.7 |
| 30 34.8 34.5 82.3 60.3 |
| 45 36.6 37.42 84.2 67.2 |
| 60 38.8 39.4 85.3 70.0 |
| 75 42.9 44.1 94.4 90.3 |
| ______________________________________ |
Nizatidine granules compared in water with tablet with 1.5% citric acid and tablet with 1.5% of citric acid and 37.5 mg of calcium carbonate.
| TABLE 6 |
| ______________________________________ |
| Time (min.) |
| Gran Tab (1.5% C.A.) |
| Tab (C.A. plus CaCO3) |
| ______________________________________ |
| 0 0 0 0 |
| 30 88.8 39.1 97 |
| ______________________________________ |
The process of Example 1 is used with 25% by weight of magnesium aluminum slicate, 5% of nizatidine, 0.25% of sodium saccharin and 1.2% of citric acid. The granules, before tabletting, were compared with the tabletted product and with the chewable tablet with 5% of calcium carbonate.
| TABLE 7 |
| ______________________________________ |
| Time Gran (Without CaCO3) |
| (With CaCO3) |
| ______________________________________ |
| 0 0 0 0 |
| 30 37 45 92.2 |
| 60 39.2 47 93 |
| 75 47.4 47.4 95.7 |
| ______________________________________ |
The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.
Caldwell, Henry C., Desai, Ashok J.
| Patent | Priority | Assignee | Title |
| 10959971, | Nov 02 2018 | NUTRITION 21, LLC | Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers |
| 11103000, | Dec 16 2019 | NUTRITION 21, LLC | Methods of production of arginine-silicate complexes |
| 11191735, | Mar 13 2015 | NUTRITION 21, LLC | Arginine silicate for periodontal disease |
| 11471435, | Nov 02 2018 | NUTRITION 21, LLC | Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers |
| 11622571, | Dec 16 2019 | Nutrition21, LLC | Methods of production of arginine-silicate complexes |
| 11850219, | Nov 12 2015 | NUTRITION 21, LLC | Inositol-stabilized arginine-silicate for hair growth and thickening |
| 11931342, | Sep 01 2016 | NUTRITION 21, LLC | Magnesium biotinate compositions and methods of use |
| 11938117, | Sep 01 2016 | NUTRITION 21, LLC | Magnesium biotinate compositions and methods of use |
| 5707970, | Feb 12 1997 | NUTRITION 21, LLC | Arginine silicate complex and use thereof |
| 5869499, | Jul 15 1993 | Pfizer Inc | Benzyloxyquinuclidines as substance P antagonists |
| 6156735, | Feb 12 1997 | NUTRITION 21, LLC | Arginine silicate inositol complex and use thereof |
| 6270807, | Mar 02 1999 | L. PERRIGO COMPANY | Taste-masked pharmaceutical composition |
| 6344444, | Feb 12 1997 | NUTRITION 21, LLC | Arginine-silicate-inositol complex and use thereof |
| 7576132, | Aug 22 2002 | NUTRITION 21, LLC | Arginine silicate inositol complex and use thereof |
| Patent | Priority | Assignee | Title |
| 3140978, | |||
| 3248290, | |||
| 3337402, | |||
| 3337403, | |||
| 3427379, | |||
| 3432593, | |||
| 3567819, | |||
| 4327076, | Nov 17 1980 | Nabisco Technology Company | Compressed chewable antacid tablet and method for forming same |
| 4711774, | Mar 27 1986 | Warner-Lambert Company | Medicament adsorbates with complex magnesium aluminum silicate and their preparation |
| 4716033, | Mar 27 1986 | Warner-Lambert Company | Medicament adsorbates with surfactant and their preparation |
| 4717565, | Mar 27 1986 | Warner-Lambert Company | Process for the preparation of medicament adsorbates |
| 4719228, | May 23 1984 | David A., Rawlins | Pharmaceutical composition |
| 4753800, | Oct 04 1985 | Warner-Lambert Company | Medicament adsorbates and their preparation |
| 4758424, | Mar 27 1986 | Warner-Lambert Company | Medicament adsorbates of decongestants with complex magnesium aluminum silicate and their preparation |
| 4758425, | Mar 27 1986 | Warner-Lambert Company | Medicament adsorbates of antiasthmatics with complex magnesium aluminum silicate and their preparation |
| 4761274, | Mar 27 1986 | Warner-Lambert Company | Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation |
| 4859709, | May 23 1984 | BEECHAM GROUP P L C | Pharmaceutical composition |
| 5057319, | Dec 23 1987 | Smith Kline Dauelsberg GmbH | Pharmaceutical compositions of cimetidine |
| 5075114, | May 23 1990 | McNeil-PPC, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
| 5084278, | Jun 02 1989 | NORTEC DEVELOPMENT ASSOCIATES, INC , NORTEC , A CORP OF NEW JERSEY | Taste-masked pharmaceutical compositions |
| 5169640, | May 08 1987 | Smith Kline & French Laboratories, Ltd. | Pharmaceutical compositions |
| 5183829, | Sep 27 1991 | DEPOMED, INC | Oral liquid compositions of non-steroidal anti-inflammatory drugs |
| 5188839, | May 08 1987 | Smith Kline & French Laboratories Ltd. | Pharmaceutical compositions of cimetidine |
| 5204118, | Nov 02 1989 | McNeil-PPC, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| 5213794, | Nov 17 1990 | Bayer Aktiengesellschaft | Antacid preparation having a prolonged gastric residence time |
| 5219563, | May 11 1988 | Glaxo Group Limited | Drug adsorbates |
| 5225197, | Apr 28 1989 | Beecham Group plc | Pharmaceutical formulation |
| 5229137, | May 06 1992 | Brigham and Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
| 5260072, | Aug 30 1990 | McNeil-PPC, Inc. | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets |
| 5275823, | Apr 27 1989 | Smith Kline & French Laboratories Ltd. | Pharmaceutical compositions |
| 5288506, | Apr 21 1988 | FORDONAL S L , A SPANISH BODY CORPORATE | Antacid compositions with prolonged gastric residence time |
| GB2222772, | |||
| WO9200102, | |||
| WO9324124, | |||
| WO9408560, | |||
| WO9408576, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Feb 02 1995 | Applied Analytical Industries, Inc. | (assignment on the face of the patent) | ||||
| Mar 31 1995 | DESAI, ASHOK J | APPLIED ANALYTICAL INDUSTRIES, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007641 | 0992 | |
| Mar 31 1995 | CALDWELL, HENRY C | APPLIED ANALYTICAL INDUSTRIES, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 007641 | 0992 | |
| Aug 27 1999 | APPLIED ANALYTICAL INDUSTRIES, INC | BANK OF AMERICA, N A , AS LENDER | GRANT OF SECURITY INTEREST | 010327 | 0408 | |
| Nov 20 2000 | APPLIED ANALYTICAL INDUSTRIES, INC | AAIPHARMA INC | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 012211 | 0703 | |
| Aug 17 2001 | AAIPHARMA INC | BANK OF AMERICA, N A , AS AGENT | NOTICE OF GRANT OF SECURITY INTEREST | 012153 | 0105 | |
| Mar 28 2002 | AAIPHARMA INC | BANK OF AMERICA, N A , AS ADMINISTRATIVE AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 012865 | 0818 | |
| Apr 23 2004 | BANK OF AMERICA, N A | AAIPHARMA INC | TERMINATION OF SECURITY INTEREST IN PATENTS | 014580 | 0812 | |
| Apr 23 2004 | AAIPHARMA INC | SILVER POINT FINANCE LLC | SECURITY AGREEMENT | 014580 | 0798 | |
| Apr 23 2004 | AAIPHARMA INC | Wachovia Bank, National Association | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 014615 | 0837 | |
| Apr 23 2004 | BANK OF AMERICA, N A | APPLIED ANALYTICAL INDUSTRIES, INC | TERMINATION OF SECURITY INTEREST IN PATENTS | 014580 | 0823 | |
| Apr 24 2004 | AAIPHARMA LLC A DELAWARE LIMITED LIABILITY COMPANY | SILVER POINT FINANCE LLC | SECURITY AGREEMENT | 014580 | 0798 | |
| Feb 28 2006 | SILVER POINT FINANCE LLC | AAIPHARMA LLC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 017262 | 0312 | |
| Mar 02 2006 | Wachovia Bank, National Association | AAIPHARMA LLC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 017262 | 0312 |
| Date | Maintenance Fee Events |
| Oct 20 2000 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Nov 11 2004 | REM: Maintenance Fee Reminder Mailed. |
| Apr 22 2005 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| May 25 2005 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Apr 22 2000 | 4 years fee payment window open |
| Oct 22 2000 | 6 months grace period start (w surcharge) |
| Apr 22 2001 | patent expiry (for year 4) |
| Apr 22 2003 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Apr 22 2004 | 8 years fee payment window open |
| Oct 22 2004 | 6 months grace period start (w surcharge) |
| Apr 22 2005 | patent expiry (for year 8) |
| Apr 22 2007 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Apr 22 2008 | 12 years fee payment window open |
| Oct 22 2008 | 6 months grace period start (w surcharge) |
| Apr 22 2009 | patent expiry (for year 12) |
| Apr 22 2011 | 2 years to revive unintentionally abandoned end. (for year 12) |